AstraZeneca(US:AZN) Zheng Quan Shi Bao Wang·2025-10-25 11:44Core Insights - AstraZeneca has officially launched its new Global Strategic R&D Center in Beijing, marking its sixth global and second in China, as part of a $2.5 billion (approximately 18 billion RMB) investment plan [1] - The Beijing center will focus on artificial intelligence and data science to accelerate the transition of early drug research results into clinical development [1] - The center aims to enhance collaboration with local clinical trial institutions, universities, and biotech companies to deepen disease understanding and foster scientific innovation [1] Company Developments - AstraZeneca's CEO Pascal Soriot emphasized that the new center will leverage Beijing's scientific ecosystem and AI advantages to expedite the development of next-generation innovative drugs [1] - The company announced multiple collaborations to promote global cooperation and accelerate new drug development, including partnerships with Cambridge University and various Beijing governmental bodies [1] - AstraZeneca is also collaborating with Hengrui Medicine in research related to oncology and autoimmune diseases, and has established a new innovation laboratory adjacent to the Beijing R&D center [1] Workforce Expansion - The deployment of these initiatives will increase AstraZeneca's workforce in Beijing to approximately 1,700 employees, further strengthening its R&D presence in China and solidifying Beijing's status as a key hub in global life sciences [2]